1. 1) Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, Wilcox I, Keech A, Rodgers A, Lal S. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327037 participants. Lancet Diabetes Endocrinol., 8, 36–49 (2020).
2. 2) Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet, 376, 1670–1681 (2010).
3. 3) Shimizu R, Torii H, Yasuda D, Hiraoka Y, Kitada T, Hashida T, Yoshimoto A, Kita T, Kume N. Serum lipid goal attainment in chronic kidney disease (CKD) patients under the Japan Atherosclerosis Society (JAS) 2012 guidelines: a single-center study. J. Atheroscler. Thromb., 22, 949–957 (2015).
4. 4) Shimizu R, Torii H, Yasuda D, Hiraoka Y, Furukawa Y, Yoshimoto A, Iwakura T, Matsuoka N, Tomii K, Kohara N, Hashida T, Kume N. Comparison of serum lipid management between elderly and non-elderly patients with and without coronary heart disease (CHD). Prev. Med. Rep., 4, 192–198 (2016).
5. 5) Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N. Engl. J. Med., 309, 288–296 (1983).